CN112546204A - Oral care solution for treating hand-foot-and-mouth disease and dental ulcer and preparation method thereof - Google Patents

Oral care solution for treating hand-foot-and-mouth disease and dental ulcer and preparation method thereof Download PDF

Info

Publication number
CN112546204A
CN112546204A CN201910851168.6A CN201910851168A CN112546204A CN 112546204 A CN112546204 A CN 112546204A CN 201910851168 A CN201910851168 A CN 201910851168A CN 112546204 A CN112546204 A CN 112546204A
Authority
CN
China
Prior art keywords
vitamin
oral care
care solution
foot
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910851168.6A
Other languages
Chinese (zh)
Inventor
蔡娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201910851168.6A priority Critical patent/CN112546204A/en
Publication of CN112546204A publication Critical patent/CN112546204A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

The invention relates to an oral care solution for treating hand-foot-and-mouth disease and dental ulcer and a preparation method thereof, wherein the oral care solution comprises the following components in parts by weight: 4IU of recombinant human insulin injection, 20ml of 0.2 percent lidocaine hydrochloride injection, 20 tablets of vitamin B complex tablets and 250ml of 0.9 percent physiological saline; the vitamin B complex tablet comprises the following components in parts by weight: 3mg of vitamin B1, 1.5mg of vitamin B2, 0.2mg of vitamin B6, 10mg of niacinamide and 1mg of calcium pantothenate. The preparation method comprises respectively injecting 4IU recombinant human insulin injection, 20ml 0.2% lidocaine hydrochloride injection and 20 vitamin B complex tablets under sterile condition, adding 250ml 0.9% normal saline, and mixing and dissolving to obtain oral care solution. The oral care solution provided by the invention contains various common medicines, and the materials are convenient to obtain. The oral care solution provided by the invention can be used for effectively resisting infection, supplementing various nutrient components and promoting epithelial cell proliferation, so that ulcer healing is accelerated, and the oral care solution can be used for effectively relieving pain and is easily accepted by children patients.

Description

Oral care solution for treating hand-foot-and-mouth disease and dental ulcer and preparation method thereof
Technical Field
The invention belongs to the technical field of oral care, and particularly relates to an oral care solution for treating hand-foot-and-mouth disease and dental ulcer and a preparation method thereof.
Background
The hand-foot-and-mouth disease (HFMD) is a common infectious disease caused by enterovirus infection, is mainly transmitted through saliva and spray through respiratory tracts, is common in summer and autumn, and is clinically manifested as the outbreak of most children patients, which can cause fever, rash of hands, feet, oral cavities and buttocks or herpes, and the life quality of some children patients is seriously reduced due to the accompanying of oral ulcer, oral pain, running water and anorexia. Researches show that the lidocaine injection can effectively relieve oral symptoms of children patients, relieve pain and has remarkable curative effect.
Most of traditional gargle has single component, and the effect has limitation, such as: compound borax liquid, chlorhexidine liquid, penicillin solution, 1-3% hydrogen peroxide, 1-4% sodium bicarbonate solution and the like. The action mechanism is as follows: local antibacterial, and changes oral pH value and oral environment, thereby inhibiting growth and reproduction of microorganism. However, children with the hand-foot-and-mouth disease and oral ulcer are younger in age and high in pain sensitivity, the traditional gargle is slow in action, oral pain symptoms of the children cannot be relieved remarkably, the pain affects the feeding of the children, and the children are easy to feel upset by family members of the children, so that the working difficulty of nursing staff is increased.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the oral care solution for treating the hand-foot-and-mouth disease and the dental ulcer.
In order to achieve the purpose, the technical scheme of the invention is as follows:
an oral care solution for treating hand-foot-and-mouth disease oral ulcer comprises the following components: recombinant human insulin injection, 0.2 percent lidocaine hydrochloride injection, vitamin B complex tablets and 0.9 percent normal saline; the vitamin B complex tablet comprises vitamin B1, vitamin B2, vitamin B6, nicotinamide and calcium pantothenate.
Further: the oral care solution comprises the following components in parts by weight: 4IU of recombinant human insulin injection, 20ml of 0.2 percent lidocaine hydrochloride injection, 20 tablets of vitamin B complex tablets and 250ml of 0.9 percent physiological saline; the vitamin B complex tablet comprises the following components in parts by weight: 3mg of vitamin B1, 1.5mg of vitamin B2, 0.2mg of vitamin B6, 10mg of niacinamide and 1mg of calcium pantothenate.
Further, the vitamin B complex tablet also comprises auxiliary materials, wherein the auxiliary materials are as follows: starch, dextrin, magnesium stearate, hydroxypropyl cellulose, sucrose and silicon dioxide.
The invention also provides a preparation method of the oral care solution for treating the hand-foot-and-mouth disease and the dental ulcer, the preparation method comprises the steps of respectively adding 4IU of recombinant human insulin injection, 20ml of 0.2% lidocaine hydrochloride injection and 20 vitamin B complex tablets into 250ml of 0.9% physiological saline, and mixing and dissolving to obtain the oral care solution under the aseptic condition of an injector.
Has the advantages that: the oral care solution provided by the invention contains various common medicines, and the materials are convenient to obtain. Among them, insulin has a main physiological effect of promoting anabolism, and accelerates repair of oral mucosal epithelium by promoting synthesis of protein. Lidocaine is a local anesthetic, and can quickly and effectively relieve pain and ensure that a child patient takes food. The vitamin B complex contains a plurality of B vitamins which are coenzyme components necessary for tissue cell metabolism, and has the functions of promoting epithelial cell function and maintaining the integrity of mucous epithelium. Therefore, the oral care solution provided by the invention can effectively resist infection, supplement various nutrient components and promote epithelial cell proliferation, so that ulcer healing is accelerated, and the oral care solution can effectively relieve pain and is easily accepted by children patients.
Detailed Description
The invention is illustrated below with reference to specific examples. It will be understood by those skilled in the art that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention in any way.
An oral care solution for treating hand-foot-and-mouth disease oral ulcer comprises the following components in parts by weight: 4IU of recombinant human insulin injection, 20ml of 0.2 percent lidocaine hydrochloride injection, 20 tablets of vitamin B complex tablets and 250ml of 0.9 percent physiological saline; the vitamin B complex tablet comprises the following components in parts by weight: 3mg of vitamin B1, 1.5mg of vitamin B2, 0.2mg of vitamin B6, 10mg of niacinamide and 1mg of calcium pantothenate; the vitamin B complex tablet also comprises auxiliary materials, wherein the auxiliary materials are as follows: starch, dextrin, magnesium stearate, hydroxypropyl cellulose, sucrose and silicon dioxide. The preparation method comprises respectively injecting 4IU recombinant human insulin injection, 20ml 0.2% lidocaine hydrochloride injection and 20 vitamin B complex tablets under sterile condition, adding 250ml 0.9% normal saline, and mixing and dissolving to obtain oral care solution.
Clinical trial using this example:
70 children patients, wherein 42 children patients are male children, 28 children patients are female children, the age is 1 month-14 years, 70 cases are divided into 2 groups, an observation group and a control group according to a numerical random method; each group had 35 infants, and all factors were balanced to make them comparable.
The observation group of children patients gargle with the product of the embodiment once in the morning, at noon, at night and before sleeping, 10 ml/time, gargle for 3 minutes, and keep using for 3 weeks, and respectively observe the curative effect on days 7, 14 and 21;
the infants in the control group were sprayed with normal saline as placebo once every 10 ml/time in the morning, at noon, at night and before sleep, gargled for 3 minutes for 3 weeks, and the treatment effect was observed on days 7, 14 and 21, respectively.
Observing and evaluating the curative effect indexes: the size of the ulcer part was measured and evaluated on days 7, 14 and 21 of oral treatment and the amount of food taken by the infant patient was recorded. The pain degree of the children patients is scored by VAS pain score, the total score is 10, 0 represents no pain, and the higher the score is, the more severe the pain is. The results are reported in Table 1.
TABLE 1
Figure DEST_PATH_IMAGE001
As a result: the healing speed of the oral ulcer of the infant patient in the observation group is obviously higher than that of the control group; the observation group nursing group for the sick children to recover the normal eating time is obviously shorter than that of the control group, and the effect of relieving the pain of the sick children is more obvious.

Claims (4)

1. An oral care solution for treating hand-foot-and-mouth disease oral ulcer is characterized by comprising the following components: recombinant human insulin injection, 0.2 percent lidocaine hydrochloride injection, vitamin B complex tablets and 0.9 percent normal saline; the vitamin B complex tablet comprises vitamin B1, vitamin B2, vitamin B6, nicotinamide and calcium pantothenate.
2. The oral care solution for treating the hand-foot-and-mouth disease and the oral ulcer according to claim 1, wherein the oral care solution comprises the following components in parts by weight: 4IU of recombinant human insulin injection, 20ml of 0.2 percent lidocaine hydrochloride injection, 20 tablets of vitamin B complex tablets and 250ml of 0.9 percent physiological saline; the vitamin B complex tablet comprises the following components in parts by weight: 3mg of vitamin B1, 1.5mg of vitamin B2, 0.2mg of vitamin B6, 10mg of niacinamide and 1mg of calcium pantothenate.
3. The oral care solution for treating the hand-foot-and-mouth disease and the oral ulcer according to any one of claims 1 or 2, wherein the vitamin B complex tablet further comprises an auxiliary material, and the auxiliary material is: starch, dextrin, magnesium stearate, hydroxypropyl cellulose, sucrose and silicon dioxide.
4. The method for preparing an oral care solution for treating hand-foot-and-mouth disease oral ulcer according to any one of claims 1 or 2, wherein the preparation method comprises the steps of respectively preparing 4IU of recombinant human insulin injection, 20ml of 0.2% lidocaine hydrochloride injection and 20 vitamin B complex tablets under the aseptic condition of a syringe, and then adding 250ml of 0.9% physiological saline for mixing and dissolving to obtain the oral care solution.
CN201910851168.6A 2019-09-10 2019-09-10 Oral care solution for treating hand-foot-and-mouth disease and dental ulcer and preparation method thereof Pending CN112546204A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910851168.6A CN112546204A (en) 2019-09-10 2019-09-10 Oral care solution for treating hand-foot-and-mouth disease and dental ulcer and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910851168.6A CN112546204A (en) 2019-09-10 2019-09-10 Oral care solution for treating hand-foot-and-mouth disease and dental ulcer and preparation method thereof

Publications (1)

Publication Number Publication Date
CN112546204A true CN112546204A (en) 2021-03-26

Family

ID=75028760

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910851168.6A Pending CN112546204A (en) 2019-09-10 2019-09-10 Oral care solution for treating hand-foot-and-mouth disease and dental ulcer and preparation method thereof

Country Status (1)

Country Link
CN (1) CN112546204A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089803A2 (en) * 2004-03-24 2005-09-29 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
CN101007069A (en) * 2007-01-12 2007-08-01 成都万芳科技发展有限公司 A medicinal composition for treating oral ulcer and its preparation method
CN101797262A (en) * 2009-02-05 2010-08-11 齐凤芹 Western medicine powder for treating dental ulcer of infant
US20100305071A1 (en) * 2007-08-30 2010-12-02 Prelief Inc. Methods for improving healing of an oral lesion using a glycerophosphate salt
CN103816418A (en) * 2014-02-28 2014-05-28 山东省立医院 Medicine for treating oral ulcer and preparation method thereof
CN106620673A (en) * 2016-12-30 2017-05-10 江阴贝瑞森生化技术有限公司 Hydrogel for treating infant dental ulcer and preparation method of hydrogel
CN106692954A (en) * 2017-03-27 2017-05-24 皖南医学院 Pharmaceutical composition for treating oral ulcer and reagent

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089803A2 (en) * 2004-03-24 2005-09-29 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
CN101007069A (en) * 2007-01-12 2007-08-01 成都万芳科技发展有限公司 A medicinal composition for treating oral ulcer and its preparation method
US20100305071A1 (en) * 2007-08-30 2010-12-02 Prelief Inc. Methods for improving healing of an oral lesion using a glycerophosphate salt
CN101797262A (en) * 2009-02-05 2010-08-11 齐凤芹 Western medicine powder for treating dental ulcer of infant
CN103816418A (en) * 2014-02-28 2014-05-28 山东省立医院 Medicine for treating oral ulcer and preparation method thereof
CN106620673A (en) * 2016-12-30 2017-05-10 江阴贝瑞森生化技术有限公司 Hydrogel for treating infant dental ulcer and preparation method of hydrogel
CN106692954A (en) * 2017-03-27 2017-05-24 皖南医学院 Pharmaceutical composition for treating oral ulcer and reagent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张晓丽: "口腔溃疡的治疗方法及研究进展探讨分析", 《临床医药文献电子杂志》, vol. 5, no. 55, pages 191 - 192 *

Similar Documents

Publication Publication Date Title
TW200826953A (en) Agonist for healing living organisms
CN102631336B (en) Freeze-drying orally disintegrating tablet with vitamin K1 composition for infants and preparation method for freeze-drying orally disintegrating tablet
CN112546204A (en) Oral care solution for treating hand-foot-and-mouth disease and dental ulcer and preparation method thereof
CN107432478A (en) A kind of compound linseed oil microcapsule powder and preparation method thereof
CN103550216A (en) Piperacillin sodium and tazobactam sodium pharmaceutical composition and preparation method thereof
CN101991548A (en) Reduced glutathione freeze-dried powder injection and preparation method thereof
CN101480412A (en) Honeybee four-treasure for treating prostatosis
CN112891383A (en) Probiotic composition for treating gynecological inflammation and preparation method thereof
CN109464655B (en) External capsule preparation for preventing and treating vaginitis
CN103239461A (en) Vitamin B complex injection and preparation method thereof
CN105663814A (en) Nutrition preparation for preventing and treating disease of respiratory system and preparation method thereof
Spiers Shigella sonnei septicaemia in a child with acute monocytic leukaemia.
JP2000050793A (en) Synthetic milk composition
CN111184762A (en) Solid preparation for cocktail therapy
CN105250227A (en) Citric acid caffeine freeze-dried powder and preparation method thereof
US11963991B2 (en) Treatment of warts
US11116808B2 (en) Treatment of warts
CN106619741A (en) Medicament for treating eczema and preparation method thereof
Brown Glossitis in Pernicious Anaemia
Verma Further experience of the treatment of superficial keratitis with riboflavin
SU686734A1 (en) Remedy for treatment of pneumonia, anemia and dyspepsia
Hoagland Para-aminobenzoic acid in the treatment of acute rheumatic fever
CN103933064A (en) Fungus remover
CN107029093A (en) A kind of Chinese medicine for treating diabetes
CN114712402A (en) Composition for treating infantile thrush and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination